322 related articles for article (PubMed ID: 28212356)
1. The seamless approach to drug development in oncology.
Pazdur R
Clin Adv Hematol Oncol; 2016 Dec; 14(12):958-959. PubMed ID: 28212356
[No Abstract] [Full Text] [Related]
2. Seamless Oncology-Drug Development.
Prowell TM; Theoret MR; Pazdur R
N Engl J Med; 2016 May; 374(21):2001-3. PubMed ID: 27074059
[No Abstract] [Full Text] [Related]
3. Accelerating identification and regulatory approval of investigational cancer drugs.
Esserman LJ; Woodcock J
JAMA; 2011 Dec; 306(23):2608-9. PubMed ID: 22187281
[No Abstract] [Full Text] [Related]
4. Accelerated approval regulations may need overhaul, panel suggests.
Finkelstein JB
J Natl Cancer Inst; 2005 Dec; 97(24):1802-4. PubMed ID: 16368938
[No Abstract] [Full Text] [Related]
5. Drug Development, Trial Design, and Endpoints in Oncology: Adapting to Rapidly Changing Science.
Blumenthal GM; Goldberg KB; Pazdur R
Clin Pharmacol Ther; 2017 May; 101(5):572-574. PubMed ID: 28074476
[TBL] [Abstract][Full Text] [Related]
6. Can single-patient investigational new drug studies hurry slow trains to the fast track?
Chenoweth D
Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
[TBL] [Abstract][Full Text] [Related]
7. Trouble at the office.
Allison M
Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
[No Abstract] [Full Text] [Related]
8. Trend toward noninferiority trials may mean more difficult interpretation of trial results.
Tuma RS
J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926
[No Abstract] [Full Text] [Related]
9. Neoadjuvant trials could speed up drug approvals.
Peres J
J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
[No Abstract] [Full Text] [Related]
10. An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs.
Leighton JK; Saber H; Reaman G; Pazdur R
Regul Toxicol Pharmacol; 2016 Aug; 79():142-143. PubMed ID: 26952647
[No Abstract] [Full Text] [Related]
11. Cancer drugs. Smart weapons prove tough to design.
Couzin J
Science; 2002 Oct; 298(5593):522-5. PubMed ID: 12386312
[No Abstract] [Full Text] [Related]
12. Regulatory issues for Data and Safety Monitoring Committees.
Fisher L; Klibaner M
Am Heart J; 2001 Apr; 141(4):536-41. PubMed ID: 11275916
[No Abstract] [Full Text] [Related]
13. An audience with Tatiana Prowell. Interviewed by Asher Mullard.
Prowell T
Nat Rev Drug Discov; 2014 Jun; 13(6):410-1. PubMed ID: 24875091
[No Abstract] [Full Text] [Related]
14. Interpretation of surrogate endpoints in the era of the 21st Century Cures Act.
Knopf K; Baum M; Shimp WS; Bennett CL; Faith D; Fishman ML; Hrushesky WJ
BMJ; 2016 Dec; 355():i6286. PubMed ID: 28039123
[No Abstract] [Full Text] [Related]
15. Should the FDA be the doctor of last resort?
DeVita VT
Nat Clin Pract Oncol; 2005 Sep; 2(9):423. PubMed ID: 16264991
[No Abstract] [Full Text] [Related]
16. Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World.
Mailankody S; Prasad V
JAMA Oncol; 2017 Jul; 3(7):889-890. PubMed ID: 27892992
[No Abstract] [Full Text] [Related]
17. Managing oncology research protocols.
Lunik MC
Top Hosp Pharm Manage; 1994 Jul; 14(2):11-21. PubMed ID: 10136201
[TBL] [Abstract][Full Text] [Related]
18. Overhauling clinical trials.
Scott CT; Baker M
Nat Biotechnol; 2007 Mar; 25(3):287-92. PubMed ID: 17344876
[No Abstract] [Full Text] [Related]
19. A US Food and Drug Administration perspective on evaluating medical products for Ebola.
Russek-Cohen E; Rubin D; Price D; Sun W; Cox E; Borio L
Clin Trials; 2016 Feb; 13(1):105-9. PubMed ID: 26768565
[No Abstract] [Full Text] [Related]
20. Researchers left to guess at outcomes of most cancer clinical trials.
Twombly R
J Natl Cancer Inst; 2009 Jan; 101(2):72-4. PubMed ID: 19141774
[No Abstract] [Full Text] [Related]
[Next] [New Search]
